Across TCGA pan-cancer cohorts, TSC22D2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TSC22D2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TSC22D2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TSC22D2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where TSC22D2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TSC22D2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.506	<.001	11	view →
CCRCC	Male	All	−0.377	<.001	11	view →
COAD	Male	All	−0.326	<.001	8	view →
LSCC	Male	All	+0.212	<.001	6	view →
LUAD	Male	All	+0.218	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TSC22D2 RNA expression & survival · all TSC22D2 data types